Immunomodulatory effects of antiangiogenic tyrosine kinase inhibitors in renal cell carcinoma models: Impact on following anti-PD-1 treatments
Biochemical Pharmacology · 2024-08 · 226 · 116397
DOI: 10.1016/j.bcp.2024.116397 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemical Pharmacology, 2024-08. Verfasst von Claudia Fumarola und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine and Surgery, University of Parma, 43126 Parma, Italy. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms, Angiogenesis Inhibitors, Protein Kinase Inhibitors. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
The approval of immune checkpoint inhibitors (ICIs) has revolutionized the management of metastatic renal cell carcinoma (RCC), introducing several ICI-based combinations as the new standard of care for affected patients. Nonetheless, monotherapy with antiangiogenic tyrosine kinase inhibitors (TKIs), such as pazopanib or sunitinib, still represents a first-line treatment option for selected patients belonging to the favorable risk group according to the International mRCC Database Consortium (IMDC) model. After TKI monotherapy, the main second-line option is represented by ICI monotherapy with the anti-Programmed Death Receptor 1(PD-1) nivolumab. To date, the expected clinical outcomes are similar with pazopanib or sunitinib and there is no clear indication for selecting one TKI over the other. Moreover, their impact on subsequent ICI treatment outcomes is not well defined, yet. Based on these premises, we investigated the immunomodulatory activity of these drugs in vitro and in vivo.Both TKIs induced Programmed Cell Death Ligand-1 (PD-L1) expression and soluble PD-L1 release in RCC cells, and hampered T cell activation, reducing cytokine production and the proportion of activated T cells. Nevertheless, in a syngeneic co-culture system with peripheral blood mononuclear cells (PBMCs) and tumor cells, incubation with anti-PD-1 antibody following TKIs treatment significantly restored T cell function, potentiating the cytotoxic effects against tumor cells. Pazopanib and sunitinib followed by anti-PD-1 antibody produced a comparable inhibition of tumor growth in a RCC syngeneic mouse model. Our findings suggest that pazopanib and sunitinib, showing similar immunomodulatory effects, may have a comparable impact on the subsequent effectiveness of PD-1/PD-L1 blockade.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine and Surgery, University of Parma, 43126 Parma, Italy.
- Department of Medicine and Surgery, University of Parma, 43126 Parma, Italy. Electronic address: mara.bonelli@unipr.it.
- Department of Occupational and Environmental Medicine, Epidemiology and Hygiene, INAIL-Italian Workers' Compensation Authority, Monte Porzio Catone, 00078 Rome, Italy.
- Pathology Unit, University Hospital of Parma, 43126 Parma, Italy.
Zitieren
APA
Fumarola, C., La Monica, S., Bonelli, M., Zoppi, S., Alfieri, R., Galetti, M., Gnetti, L., Campanini, N., Pozzi, G., Cavazzoni, A., Mazzaschi, G., Silini, E. M., Buti, S., & Petronini, P. G. (2024). Immunomodulatory effects of antiangiogenic tyrosine kinase inhibitors in renal cell carcinoma models: Impact on following anti-PD-1 treatments. Biochemical Pharmacology, 226, 116397. https://doi.org/10.1016/j.bcp.2024.116397
Vancouver
Fumarola C, La Monica S, Bonelli M, Zoppi S, Alfieri R, Galetti M, et al. Immunomodulatory effects of antiangiogenic tyrosine kinase inhibitors in renal cell carcinoma models: Impact on following anti-PD-1 treatments. Biochemical Pharmacology. 2024;226:116397. doi:10.1016/j.bcp.2024.116397
BibTeX
@article{Fumarola2024,
author = {Fumarola, Claudia and La Monica, Silvia and Bonelli, Mara and Zoppi, Silvia and Alfieri, Roberta and Galetti, Maricla and Gnetti, Letizia and Campanini, Nicoletta and Pozzi, Giulia and Cavazzoni, Andrea and Mazzaschi, Giulia and Silini, Enrico Maria and Buti, Sebastiano and Petronini, Pier Giorgio},
title = {Immunomodulatory effects of antiangiogenic tyrosine kinase inhibitors in renal cell carcinoma models: Impact on following anti-PD-1 treatments},
journal = {Biochemical Pharmacology},
year = {2024},
volume = {226},
pages = {116397},
doi = {10.1016/j.bcp.2024.116397}
}
EUVIMED